About Richter Gedeon
Richter Gedeon is a publicly listed company. Pharmaceutical manufacturing, research, and marketing in Hungary. Richter Gedeon has completed 2 acquisitions, including Finox Biotech and PregLem. Richter Gedeon offers products and services including Cariprazine and Biosimilars. Its focus areas include Pharmaceuticals, Drug Manufacturing, Research and Development and Biotechnology. Its legal entity is Richter Gedeon Nyrt.
Company details
Richter Gedeon is identified as a Hungarian-based multinational pharmaceutical company that engages in vertically integrated activities, including drug manufacturing, research and development, commerce, and marketing. Original research, womens health, and biotechnology are emphasized to deliver high-value products across various therapeutic areas. A workforce exceeding 1200 in RD positions it as a key player in Central and Eastern Europe, with a history dating back to 1901. Sustainability is addressed through long-term practices and social responsibility, ensuring innovative solutions for patients worldwide while maintaining ethical standards in operations. This approach supports its strategy to become a prominent midpharma entity in Europe.
- Stage Public
- SectorsHealthcare
- Website richter.hu
- Social LinkedIn Facebook
- Legal Name Chemical Works Of Gedeon Richter Plc
- Annual Revenue$2.83 B (USD)8.33as on Dec 31, 2025
- Net Profit$708.81 M (USD)-2.89as on Dec 31, 2025
- EBITDA$1.1 B (USD)22.65as on Dec 31, 2025
- Investments & AcquisitionsFinox Biotech
& 1 more
Products & Services of Richter Gedeon
Richter Gedeon offers a comprehensive portfolio of products and services, including Cariprazine and Biosimilars.
This drug is used for treating psychiatric conditions and is developed as part of efforts in original research within the pharmaceutical sector.
Biosimilars are produced for treating conditions like osteoporosis and are manufactured through processes that emphasize innovation and therapeutic efficacy.
People of Richter Gedeon
37 people are tracked at Richter Gedeon (17 in leadership, 16 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Tibor Horváth | Commercial Director | Leadership |
Zsolt Safranka Dr. | Global Head Of Field Force Operations | Leadership |
Gábor Orbán | CEO | Leadership |
Rita Utasi-Peszlen | Head Of Hr Operations | Leadership |
Attila Szènàsi | Chief Operating Officer | Leadership |
Viktor Dávid | Head Of Information Technology Department | Leadership |
Gabor Szucs | Director Of Financial Operations | Leadership |
Zoltán Hudivók Pharm.d. | Site Quality Head | Leadership |
Katalin Losteiner-Fogassy | Head Of Biotechnology CDMO Project Management Office | Leadership |
Ádám Nagy | Head Of Project Methodology & Data Management | Leadership |
Kristóf Bozó Pharmd | Head Of Sterile Liquid Dosage Forms Packaging Plant | Leadership |
Matthieu Lehmann | Senior Director, Business Development & Market Insights Lead, Fertility | Leadership |
Janos Penzes | Global Head Of Digital Center Of Excellence | Leadership |
Mogyorós Attila | Head Of Portfolio Project Management Office | Leadership |
Emese Pál | Head Of GCP Quality Assurance Department | Leadership |
Szilvia Módra Pharmd | Head Of Department | Leadership |
Miklós Gondolovics | Head Of IT PMO | Leadership |
László Szabó | Director | Board & advisors |
Lívia Pavlik | Board Member | Board & advisors |
Zoltán Matos | Board Member | Board & advisors |
17 more people are available in the full profile.
Complete people profiles for Richter Gedeon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Richter Gedeon
Richter Gedeon is a publicly listed company on the BET with ticker symbol RICHTER in Hungary, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Nov 1994
- Listed onBET: RICHTER
- Listed entityChemical Works of Gedeon Richter Plc
- Exchange sectorHealth technology
- ISINHU0000123096
- Share price12,610.00 HUF (+2.94% on the day) · 2026-10-14
- Market capitalisation2,239,948,463,440.00 HUF
- Price to earnings10.7
- EPS (diluted, trailing year)1,181.37 HUF
- Dividend yield5.35%
- Volume (last session)36,440
Financials of Richter Gedeon
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 928.96B HUF | 232.34B HUF | 361.29B HUF |
| 2024 | 857.54B HUF | 239.24B HUF | 294.58B HUF |
| 2023 | 805.16B HUF | 158.85B HUF | 277.35B HUF |
| 2022 | 802.75B HUF | 169.08B HUF | 217.03B HUF |
| 2021 | 630.60B HUF | 139.63B HUF | 184.70B HUF |
Detailed financial statements for Richter Gedeon
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Richter Gedeon
Richter Gedeon has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Finox Biotech and PregLem.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Fertility products are developed by this Swiss biopharma firm. | finoxbiotech.com | Kirchdorf, Switzerland | 2007 | Jun 2016 | $193.8M | |
Innovative drugs for women's reproductive medicine are developed and commercialized. | preglem.com | Geneva, Switzerland | 2006 | Oct 2010 | $155.6M |
Complete acquisition details for Richter Gedeon
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Richter Gedeon
3 dated milestones of Richter Gedeon across 22 years, from founding to its latest funding, stage changes and deals.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires PregLem.
- Acquisition Acquires Finox Biotech.
Web traffic of Richter Gedeon
Websites that share an audience with Richter Gedeon (richter.hu).
Websites whose visitors overlap most with Richter Gedeon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| serono.com | 100% | View details | |||
| ferring.com | 80% | 39.6K | #709,223 | View details | |
| ucb.com | 47% | 146.5K | #308,606 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Richter Gedeon
Complete news archive for Richter Gedeon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Richter Gedeon
Annual revenue of Richter Gedeon is $2.83B as on Dec 31, 2025.
Richter Gedeon is identified as a Hungarian-based multinational pharmaceutical company that engages in vertically integrated activities, including drug manufacturing, research and development, commerce, and marketing. Original research, womens health, and biotechnology are emphasized to deliver high-value products across various therapeutic areas. A workforce exceeding 1200 in RD positions it as a key player in Central and Eastern Europe, with a history dating back to 1901. Sustainability is addressed through long-term practices and social responsibility, ensuring innovative solutions for patients worldwide while maintaining ethical standards in operations. This approach supports its strategy to become a prominent midpharma entity in Europe.
Richter Gedeon offers Cariprazine and Biosimilars.
Yes, Richter Gedeon is publicly traded on BET under the ticker symbol RICHTER.
Richter Gedeon has made 2 acquisitions, including Finox Biotech, and PregLem.
Richter Gedeon operates through Richter Gedeon Nyrt.

